CORONA Remedies Limited has informed the Exchange regarding 'Annual Secretarial Compliance Report for the year ended March 31, 2026'.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CORONA Remedies Limited has filed its Annual Secretarial Compliance Report for FY 2025-26 with both BSE and NSE, as required under SEBI Listing Regulations. The report was prepared by Practicing Company Secretaries Dhara Patel and covers compliance with key SEBI regulations including LODR 2015, ICDR, SAST, PIT, and Depositories regulations. The secretarial auditor examined documents, filings, and website disclosures on a test-check basis. All 12 compliance areas examined received a 'Yes' status, including secretarial standards, policy adoption, website disclosures, director disqualification checks, document preservation, performance evaluation, related party transactions, insider trading compliance, and disclosure requirements. No deviations, violations, or actions by SEBI or stock exchanges were noted during the review period.
A clean secretarial compliance report with no observations or deviations is positive for shareholders as it confirms the company maintains proper board processes and statutory compliance mechanisms. This reduces regulatory risk and supports governance quality, which could be viewed favorably by investors.